2 recruiting, 1 suspended. 2 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Recruiting 2 |
| Early Phase 1 | 1 | Suspended 1 |
Follow chimeric antigen receptor gene modified T cells: new trials by email Literature Review of chimeric antigen receptor gene modified T cells trials Research Report on chimeric antigen receptor gene modified T cells
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD30 CAR-T in the Treatment of CD30 Positive Lymphoma chimeric antigen receptor gene modified T cells - Lymphoma, B Cell Lymphoma | Early Phase 1 | Suspended | Shandong Qilu Cell Therapy Engineering Technology Co., Ltd | 15 | 2026-03-01 | 2026-09-28 |
| CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma chimeric antigen receptor gene modified T cells - Lymphoma, B-Cell | Not applicable | Recruiting | Shanxi Bethune Hospital | 15 | 2025-09-05 | 2025-02-27 |
| A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors chimeric antigen receptor gene modified T cells - Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin | Not applicable | Recruiting | Shanxi Bethune Hospital | 45 | 2023-12-01 | 2025-01-20 |
Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Shanxi Bethune Hospital (2) · Shandong Qilu Cell Therapy Engineering Technology Co., Ltd (1)
China (3)